RxDoctor Payments Data

Ellen Nguyen

Optometrist · Raceland, LANPI 1366754996

Payments from drug & device makers

$1,361in general payments, 2019–2025

Across 36 payments — averaging $37.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$552
  • Oyster Point Pharma, Inc.$174
  • Bausch & Lomb Americas Inc.$164
  • Shire North American Group Inc$162
  • Aerie Pharmaceuticals, Inc.$57
  • Carl Zeiss Meditec, Inc.$50
  • plus $201 from 8 others

What the payments were for

  • Food & beverage$1,32497%
  • Gifts$373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,361 in reported general payments places this provider in the 55th percentile of 500 optometrist providers in Louisiana.

See all optometrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$24,980
Medicare patients
144
Services billed
329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine11$16,238
Azelastine Hcl75$2,476
Latanoprost192$1,541
Travoprost12$967
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$721
Prednisolone Acetate25$700
Timolol Maleate30$277
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha19$262
Brimonidine Tartrate34$261
Dorzolamide Hcl12$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$34$16,23811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 500 optometrist providers in Louisiana.

Other optometrist in Raceland

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →